- MeSH
- Anticoagulants MeSH
- Antithrombins classification adverse effects MeSH
- Platelet Aggregation Inhibitors MeSH
- Cardiac Surgical Procedures * MeSH
- Cardiovascular Diseases surgery complications MeSH
- Hematologic Diseases * classification complications MeSH
- Blood Cell Count MeSH
- Humans MeSH
- Leukocyte Count classification MeSH
- Postoperative Complications * MeSH
- Postoperative Hemorrhage etiology chemically induced classification prevention & control MeSH
- Risk Factors MeSH
- Thrombophilia diagnosis etiology MeSH
- Warfarin adverse effects MeSH
- Check Tag
- Humans MeSH
Vysokodávkovaná chemoterapie s autologní transplantací hematopoetických progenitorových buněkje možností léčby u vysoce rizikových onkologických pacientů. Periferní kmenové buňky (PBSC) seseparují na Autotransfuzní jednotce v IKEM od listopadu 96. Do konce září 2002 bylo indikováno kesběru PBSC 64 pacientů se solidními tumory (47 mužů a 17 žen). Separace PBSC byly zahájeny přivzestupu hodnot CD 34+ buněk nad 20 x 103/ml v periferní krvi po mobilizaci kombinací chemoterapies růstovými faktory – G-CSF (Neupogen v dávce 15 µg/kg/den). Celkem bylo provedeno 247 separací naseparátorech Haemonetics MCS 3p a MCS+. Byly srovnávány oba typy separátorů. Všichni nemocnídostali koncentráty PBSC zpět: 40 pacientů po aplikaci vysokodávkované a 24 pacientů po aplikaciintenzifikované chemoterapie. Tento postup se do budoucna jeví jako velice perspektivní pro tutoskupinu nemocných.
High - dose chemotherapy with autologous transplantation of peripheral blood progenitor cells isa possible treatment for the high-risk oncology patients. Peripheral blood stem cells (PBSC) have beenseparated on Autotransfusion detachment in IKEM Prague since November 1996. By the end ofSeptember 2002, 64 patients (47 man and 17 women) with solid tumours were indicated for collections.PBSC separations were commenced at value CD 34+ peripheral blood cells over 20 x 103/ml aftermobilization by combination of chemotherapy with growth factors - G-CSF (Neupogen in dose 15µg/kg/day). There were 247 separations provided on the whole on the Haemonetics MCS 3p and MCS+separators, respectively. Both types of separators were compared. All the patients were given extractPBSC extracts back: 40 patients after the application of high – dose chemotherapy and 24 patients afterthe application of only intensificated therapy. This procedure appears to be very perspective for thisgroup of patients in the future.
- MeSH
- Transplantation, Autologous MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Hematopoietic Stem Cell Mobilization methods MeSH
- Neoplasms drug therapy therapy MeSH
- Antineoplastic Agents administration & dosage therapeutic use MeSH
- Growth Substances administration & dosage therapeutic use MeSH
- Blood Component Removal methods instrumentation MeSH
- Hematopoietic Stem Cell Transplantation MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Review MeSH
